J&J says it will be 2014 before new Doxil contractor is approved; Merck KGaA invests in lighting;

@EricPFierce: Hospira faces more vial problems. FDA and co. say glass strands pose potential health threat. More | Follow @EricPFierce

> A new report from CPhI says that even as drugmakers are developing more antibody-drug conjugates, there are not many contract manufacturers with the capability to handle both biologics and highly potent small molecules, which will put a strain on ADC manufacturing. Report (PDF)

> Ghana officials have taken into custody the owner of an Indian company that they have accused of manufacturing a fake malaria treatment. Story

> Court filings say it will be the end of 2014 before Johnson & Johnson ($JNJ) will be able to get new plants approved to make its ovarian cancer drug Doxil, which the company says will soon be in short supply because of on-going problems at Boehringer Ingelheim's Bedford, OH, plant. Story

> U.K.-based MedPharma, which specializes in the development of topical and transdermal formulations for pre-clinical trials, has opened a new £500,000 ($800,000) investment is in a facility in Guildford, with hopes to double its business in the next 5 years. Story

> GlaxoSmithKline ($GSK) will invest €2.2 million to expand its packaging capabilities in Greece so that it can add four over-the-counter drugs to its portfolio there. Release

And Finally... Merck KGaA intends to invest further in Israel-based QLight Nanotech, a company developing LCD light products. Story